Iinfliximab
INFLIXIMAB
- TNFα inhibitor drug.
- Is chimeral monoclonal antibody against TNFα.
- Mainly used in autoimmune diseases.
Note on TNFα:
- TNFα secreted by activated macrophages & other immune cells.
- Acts on TNF receptors located on surface of neutrophils, fibroblasts & endothelial cells.
- TNFα amplifies immune inflammation by releasing cytokines & enzymes (like collagenases & metalloproteinases).
MECHANISM OF ACTION:
- Binds & inactivates TNFα.
INDICATIONS:
- In severe active Crohn’s Disease (CrD) – Fistulating type.
- In severe Ulcerative Colitis (UC) un-improved with i.v. corticosteroids & immunosuppressants.
- As i.v. infusion every 2–8 weeks, decreases acute flare-ups & helps in fistula closure.
- Therapy is continued as maintenance.
In refractory rheumatoid arthritis:
- As i.v injection every 4–8 weeks along with Methotrexate (Mtx).
- Psoriasis.
- Ankylosing spondylitis.
CONTRA-INDICATIONS:
In SLE.
- Because TNF-α is already under-expressed in SLE.
- Hence, anti-TNF drugs may cause SLE as adverse effect.
SIDE EFFECTS:
- Produces substantial toxicity including,
- Acute reactions.
- Formation of antibodies.
- Lowering of resistance to infections.
- Hence, only a reserve drug for selected patients with refractory disease.
- Cause SLE.
Exam Question
- Infliximab is a TNFα inhibitor drug.
- Infliximab is mainly indicated in severe active fistulating type of Crohn’s Disease (CrD) & in severe Ulcerative Colitis (UC).
- Infliximab is chimeral monoclonal antibody against TNFα, which binds & inactivates TNFα.
Don’t Forget to Solve all the previous Year Question asked on Iinfliximab
